Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1202P - Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)


21 Oct 2023


Poster session 13


Cancer in Special Situations/ Populations;  Cancer Research

Tumour Site

Neuroendocrine Neoplasms


Claudia von Arx


Annals of Oncology (2023) 34 (suppl_2): S701-S710. 10.1016/S0923-7534(23)01264-4


C. von Arx1, L. Cannella2, A.L. Marretta3, A. Bracigliano4, F. Tatangelo5, O. Clemente2, D. Iervolino5, V. Granata6, C. Mocerino7, R. Modica8, A. Pizzolorusso2, A. Bianco9, F. Picozzi2, A. Di Sarno3, S. Tafuto2

Author affiliations

  • 1 Department Of Breast And Thoracic Oncology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 2 Sarcomas And Rare Tumors Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 3 Clinical Medicine & Surgery Department, Azienda Ospedaliera Universitaria Federico II, 80131 - Napoli/IT
  • 4 Nuclear Medicine, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 5 Pathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 6 Radiology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 7 U.o.c. Oncology, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli - AORN A. Cardarelli, 80131 - Napoli/IT
  • 8 Clinical Medicine And Surgery Department, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, 80131 - Napoli/IT
  • 9 Medical Oncology Unit, Azienda Ospedaliera Dei Colli-Monaldi, 80131 - Napoli/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1202P


There is no consensus on the second-line regimen for pts with progressive NEC. These patients (pts) generally have poor performance status (PS) and low tolerance to combination therapy. Metronomic TMZ showed, in retrospective trials, a good safety and efficacy profile. This trial aims to assess the efficacy of TMZ given every other week in pts with advanced platinum-pretreated grade 3 (G3) poorly-differentiated neuroendocrine neoplasms (NEN) and NEC.


TENEC is an open-label, non-randomized, phase II trial that recruited pts with platinum-pre-treated metastatic neuroendocrine carcinoma. Pts received 75 mg/m2/day of TMZ for 7 days followed by 7 days of no treatment (regimen 1 week on/1 week off). The primary endpoint was the overall response rate (ORR) analysed by the Kaplan-Meier method. Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety and tolerability.


From 2017 to 2020, 38 pts were enrolled. The median age of enrolled pts was 61.5 years (25–77). Two pts (5.3%) had an Eastern Cooperative Oncology Group (ECOG) PS score of 0, 58% had an ECOG PS score of 1, 34% had an ECOG PS score of 2 and 3% had an ECOG PS score of 3. Among the pts with determined Ki67, 33.3% had a Ki67 index <55%, and 66.6% had Ki67 index ≥55%. Thirteen pts (34%) had metastases in a single site, 12 pts (31%) had two different sites of metastasis, and six pts (15%) had metastases in three or more sites. ORR was 18%, including one complete response and six partial responses. The median PFS was 6.5 months (95% CI: 5.1–14.5), and the median OS was 12 months (95% CI: 5.6–20.8). The 1-year PFS rate was 37%. No statistically significant difference in median OS (p=0.81, hazard ratio [HR] 95% CI: 0.5–1.9) and median PFS (p=0.85, HR 95% CI: 0.4–2) was observed among pts with Ki67 <55% vs ≥55%. Nausea, diarrhoea and abdominal pain were the most common adverse.


One-week-on/one-week-off TMZ shows promising activity in pts with NEN G3 and NEC. The excellent safety profile confirmed the possibility of using this scheme in pts with poor performance status. Randomised trials are warranted to confirm treatment benefits showed in this trial.

Clinical trial identification

EudraCT 2016-005238-31; NCT04122911.

Editorial acknowledgement

Legal entity responsible for the study

Salvatore Tafuto.


Has not received any fundingˆ.


C. von Arx: Financial Interests, Personal, Advisory Board, Receipt of consultation fees:Participation in a company sponsored speaker’s bureau: AstraZeneca; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, Gentili, Lilly, Novartis, Ipsen; Financial Interests, Personal, Other, Conference Fee and travel grant: Organon; Financial Interests, Personal, Other, Conference fee and travel grant: AAA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.